The FDA has granted its stamp of approval to Rezzayo, an injection jointly developed by Cidara Therapeutics and Melinta Therapeutics, to treat candidemia and invasive candidiasis. Rezzayo is a groundbreaking solution to help fight the potentially lethal infections caused by fungal pathogens.
Rezzayo, the first new echinocandin to be approved in over a decade, is a revolutionary, once-weekly injection that promises to revolutionize the way we treat fungal infections. With this breakthrough, patients can look forward to a simpler, more convenient regime for treating their condition.
The CDC issued a stark warning on Monday: a dangerous new fungus with antimicrobial resistance has been found in U.S. healthcare facilities. This fungus is capable of causing serious health complications and must be taken seriously. Healthcare professionals and patients alike must be on the lookout for this emerging threat and act quickly to prevent any potential spread.
In 2021, the CDC reported a shocking tripling of cases of Candida auris (C. auris), a fungus which poses a greater risk to those with weakened immune systems or those using invasive medical devices.
Fortunately, healthy individuals remain largely protected from the threat of this fungus, though echinocandins, the primary drugs used to treat infection, are becoming increasingly resistant.
Rezzayo offers a potential treatment option for adults with limited or no alternatives for candidemia and invasive candidiasis. With its potential to combat these difficult-to-treat fungal infections, Rezzayo can provide hope and relief to those suffering from this condition.
Rezzayo has recently been approved by the FDA under the Priority Review program after a successful Phase III trial. Rezzayo proved to be just as effective as the standard of care, caspofungin taken once daily, while also boasting a comparable safety profile. This approval is a major breakthrough in the fight against fungal infections.
John Harlow, chief commercial officer at Melinta, recently revealed the exciting news about Rezzayo and how it differs from the standard of care. According to Harlow, Rezzayo stands out from the rest by offering a unique combination of efficacy and safety that has never been seen before. With its groundbreaking approach, Rezzayo is sure to revolutionize the way in which we approach healthcare.
Rezzayo stands apart from the current standard of care with its weekly IV dosing, which eliminates the need for daily infusions. Moreover, its pharmacokinetics enable front-loaded dosing that accelerates fungal clearance in the clinic and prevents resistance development due to initial drug exposure and underdosing.
Candidemia is a serious and potentially life-threatening infection caused by the Candida fungus. It is the most common form of invasive candidiasis and a leading cause of bloodstream infections in hospitalized patients, resulting in longer hospital stays and an estimated mortality rate of 19-24%. Unfortunately, this fungal infection can be fatal, making it essential for those who are at risk to be aware of the signs and symptoms.
Melinta is poised to tap into its expansive commercial infrastructure and experience launching anti-infective drugs into acute care settings to deliver much-needed relief to patients across the globe. According to Christine Ann Miller, CEO of Melinta, this is a crucial part of their mission to make a positive difference in people’s lives.
Rezzayo is set to launch in the United States this summer in 2023, bringing a revolutionary new platform for users to explore and experience. With its innovative features, Rezzayo promises users the ultimate in convenience and accessibility. Get ready to revolutionize your online experience starting this summer!
Rezzayo is on a mission to protect adults undergoing allogeneic blood and marrow transplants from fungal diseases. Through rigorous research and clinical trials, they are striving to ensure that these individuals can safely receive treatment and live healthier lives.
Cidara’s antifungal is the latest addition to Melinta’s commercial portfolio, marking the seventh approved drug in its range. It is also the first marketed drug from Cidara, a major milestone in the company’s history.
Last year, Melinta acquired exclusive rights to commercialize the drug in the U.S., while Cidara retained rights in Japan and Mundipharma licensed the injectible for all other areas. Now, the European Medicines Agency is reviewing the application for approval in Europe, sparking anticipation of further growth in the drug’s availability.
Rezzayo’s approval has been a major win for Cidara, triggering a $20 million milestone payment from Melinta and opening the door for potential further regulatory and commercial milestone payments of up to $410 million. With this success, Cidara stands to gain a significant financial boost.